Complete Metabolic Response Assessed by FDG PET/CT to FOLFIRI-Aflibercept in Second-Line Treatment of Metastatic Colorectal Cancer

被引：2
|
作者：
Amrane, Karim [1 ]
Ollivier, Luc [2 ]
Salaun, Pierre-Yves [3 ,4 ]
Metges, Jean-Philippe [1 ]
Abgral, Ronan [3 ,4 ]
机构：
[1] Univ Hosp Brest, Dept Oncol, 2 Ave Foch, F-29609 Brest, France
[2] Univ Hosp Brest, Dept Radiotherapy, Brest, France
[3] Univ Hosp Brest, Dept Nucl Med, Brest, France
[4] Bretagne Loire Univ, EA GETBO 3878, IFR 148, Brest, France
来源：
CLINICAL NUCLEAR MEDICINE | 2019年 / 44卷 / 07期
关键词：
mCRC; FOLFIRI-aflibercept; FDG PET; CT; BEVACIZUMAB; OXALIPLATIN; PATIENT; FOLFOX;
D O I：
10.1097/RLU.0000000000002611
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
FOLFIRI-aflibercept chemotherapy is indicated in second-line treatment of metastatic colorectal cancer (mCRC) after progression under FOLFOX (+/- bevacizumab). Nevertheless, its proven therapeutic efficacy in clinical trials was based on partial responses. And to date, only 2 cases of complete response assessed by CT were reported in literature. We report a complete metabolic response assessed by FDG PET/CT in a 50-year-old woman with mCRC treated by FOLFIRI-aflibercept. This also confirms that FDG PET/CT is emerging as a useful approach for therapeutic assessment of targeted drugs in mCRC.
引用
收藏
页码：578 / 579
页数：2
相关论文
共 50 条
  • [1] Folfiri-aflibercept vs folfiri-bevacizumab as second line treatment of RAS mutated metastatic colorectal cancer in real practice
    Ottaiano, A.
    Capozzi, M.
    De Divitiis, C.
    Cassata, A.
    De Stefano, A.
    Tafuto, S.
    Avallone, A.
    Nasti, G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial
    Garcia-Alfonso, P.
    Elez, E.
    Soto-Alsar, J.
    Paez, D.
    Fernandez-Montes, A.
    Grana, B.
    Salud, A.
    Yubero, A.
    Gomez-Espana, M. A.
    Macias, I.
    Quintero, G.
    Lopez-Lopez, C.
    Fernandez-Rodriguez, T.
    Gravalos, C.
    Gonzalez-Flores, E.
    Guix, M.
    Paredes, B. Garcia
    Reina, J. J.
    Mowbray, J. R. Rodriguez
    Sastre, J.
    Aranda, E.
    ESMO OPEN, 2024, 9 (12)
  • [3] Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
    Ottaiano, Alessandro
    Capozzi, Monica
    Tafuto, Salvatore
    De Stefano, Alfonso
    De Divitiis, Chiara
    Romano, Carmela
    Avallone, Antonio
    Nasti, Guglielmo
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [4] Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer
    Denda, Tadamichi
    Sakai, Daisuke
    Hamaguchi, Tetsuya
    Sugimoto, Naotoshi
    Ura, Takashi
    Yamazaki, Kentaro
    Fujii, Hirofumi
    Kajiwara, Takeshi
    Nakajima, Takako Eguchi
    Takahashi, Shin
    Otsu, Satoshi
    Komatsu, Yoshito
    Nagashima, Fumio
    Moriwaki, Toshikazu
    Esaki, Taito
    Sato, Takeo
    Itabashi, Michio
    Oki, Eiji
    Sasaki, Toru
    Sunaga, Yoshinori
    Ziti-Ljajic, Samira
    Brillac, Claire
    Yoshino, Takayuki
    CANCER SCIENCE, 2019, 110 (03) : 1032 - 1043
  • [5] A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer
    Jo, H.
    Lee, M-S
    Lee, Y-P
    Kim, H.
    Hong, J. Y.
    Lee, J.
    Park, S. H.
    Park, J. O.
    Park, Y. S.
    Lim, H. Y.
    Kang, W. K.
    Kim, S. T.
    CLINICAL ONCOLOGY, 2022, 34 (08) : E323 - E328
  • [6] Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol
    Ottaiano, Alessandro
    Scala, Stefania
    Santorsola, Mariachiara
    Trotta, Anna Maria
    D'Alterio, Crescenzo
    Portella, Luigi
    Clemente, Ottavia
    Nappi, Anna
    Zanaletti, Nicoletta
    De Stefano, Alfonso
    Avallone, Antonio
    Granata, Vincenza
    Notariello, Carmen
    Luce, Amalia
    Lombardi, Angela
    Picone, Carmine
    Petrillo, Antonella
    Perri, Francesco
    Tatangelo, Fabiana
    Di Mauro, Annabella
    Albino, Vittorio
    Izzo, Francesco
    Rega, Daniela
    Pace, Ugo
    Di Marzo, Massimiliano
    Chiodini, Paolo
    De Feo, Gianfranco
    Del Prete, Paola
    Botti, Gerardo
    Delrio, Paolo
    Caraglia, Michele
    Nasti, Guglielmo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [7] Treatment of metastatic colorectal Cancer Aflibercept/FOLFIRI can be widely used in the second Therapy Line
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (06) : 358 - 358
  • [8] Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience
    Lavacchi, Daniele
    Roviello, Giandomenico
    Giommoni, Elisa
    Dreoni, Lorenzo
    Derio, Silvia
    Brugia, Marco
    Amedei, Amedeo
    Pillozzi, Serena
    Antonuzzo, Lorenzo
    CANCERS, 2021, 13 (15)
  • [9] XELIRI compared with FOLFIRI as a second-line treatment in patients with. metastatic colorectal cancer
    Cui, Chengxu
    Shu, Chang
    Yang, Yi
    Liu, Junbao
    Shi, Shuping
    Shao, Zhujun
    Wang, Nan
    Yang, Ting
    Hu, Songnian
    ONCOLOGY LETTERS, 2014, 8 (04) : 1864 - 1872
  • [10] Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer
    Amrane, Karim
    le Pennec, Romain
    Schick, Ulrike
    Metges, Jean-Philippe
    Abgral, Ronan
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (09) : 707 - 708
12345